Nimodipin Hexal (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on vascular smooth muscle, especially within cerebral arteries. This inhibition reduces calcium entry into the cells, causing vasodilation and preventing the narrowing (vasospasm) that can occur after a subarachnoid hemorrhage, thereby supporting cerebral perfusion.

The specific dose and dosing schedule of Nimodipin Hexal are determined by the prescribing physician based on the patient’s clinical condition, weight, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal prevention of vasospasm while minimizing adverse effects.

Safety data for nimodipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimodipine is a dihydropyridine calcium channel blocker with a high affinity for cerebral vessels, making it particularly effective for preventing vasospasm after subarachnoid hemorrhage. Other vasodilators, such as nitroglycerin or other calcium channel blockers, may have broader systemic effects and are not as specifically targeted to the brain’s vasculature.

Nimodipin Hexal should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture, heat, and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually in tablet form, as directed by the prescribing clinician. It is commonly administered with or without food, depending on the physician’s instructions, and patients should follow the exact schedule provided to ensure consistent plasma levels.

Serious adverse events, though rare, include severe hypotension, bradycardia, significant hepatic dysfunction, and allergic reactions such as rash or angioedema. Patients should be monitored for these signs, and any sudden changes in blood pressure or heart rate warrant immediate medical attention.

Nimodipin Hexal is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. It should also be avoided in individuals taking strong CYP3A4 inhibitors or other potent vasodilators without close medical supervision, as these combinations can lead to dangerous drops in blood pressure.